JAGUAR HEALTH, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-06-30 was 0.00 shares.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-03-31 was 0.00 shares.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-12-31 was -555.00 shares.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-09-30 was 555.00 shares.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 0.00 shares.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2018 was 0.00 shares.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2017 was 0.00 shares.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2016 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | 0.00 shares derived: sum of 4 quarters · filed 2021-08-13 |
| 2021-03-31 | 0.00 shares 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -555.00 shares derived: 10-Q 12 month − 10-Q 9 month · filed 2021-05-17 | 0.00 shares 10-Q · filed 2021-05-17 |
| 2020-09-30 | 555.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | |
| 2019-12-31 | 0.00 shares 10-K · filed 2021-03-31 | |
| 2018-12-31 | 0.00 shares 10-K · filed 2019-04-10 | |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | 0.00 shares 10-K · filed 2019-04-10 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | 0.00 shares derived: sum of 4 quarters · filed 2018-04-09 |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2017-08-09 | |
| 2017-03-31 | 0.00 shares 10-Q/A · filed 2017-06-23 | |
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | 0.00 shares 10-K · filed 2018-04-09 |
| 2016-03-31 | 0.00 shares 10-Q/A · filed 2017-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |